☆ 4.8 Article

Cutaneous melanoma

LANCET (2023)

Related references

Note: Only part of the references are listed.

Article Dermatology

Differences in sentinel lymph node biopsy utilization in eligible melanoma patients treated with Mohs micrographic surgery or wide local excision: A population-based logistic regression model and survival analysis

Thomas J. Knackstedt

Summary: This study compares the utilization of sentinel lymph node biopsy (SLNB) in patients undergoing wide local excision (WLE) or Mohs micrographic surgery (MMS). The findings suggest that patients receiving WLE are more likely to undergo SLNB.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2023)

Add to Collection

Article Oncology

Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation- positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study

Paolo A. Ascierto et al.

Summary: The phase 3 IMspire150 study showed improved investigator-assessed progression-free survival with atezolizumab, vemurafenib, and cobimetinib in patients with BRAFV600 mutation-positive melanoma. However, the interim overall survival analysis did not demonstrate a significant improvement in overall survival compared to the control group.

LANCET ONCOLOGY (2023)

Add to Collection

Article Oncology

Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)

Jeffrey S. Weber et al.

Summary: The CheckMate 915 trial compared adjuvant nivolumab plus ipilimumab with nivolumab alone in patients with resected melanoma. The study found that there was no significant difference in recurrence-free survival between the two treatment groups.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Add to Collection

Article Oncology

Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial

Paolo A. A. Ascierto et al.

Summary: This study is a randomized, three-arm, noncomparative phase II trial that aims to explore sequential immunotherapy and BRAF/MEK inhibition for patients with BRAFV600-mutant metastatic melanoma. The results show that sequential immunotherapy and targeted therapy provide clinically meaningful survival benefits for patients.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Add to Collection

Article Oncology

Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134

Michael B. Atkins et al.

Summary: Combination programmed cell death protein 1/cytotoxic T-cell lymphocyte-4-blockade and dual BRAF/MEK inhibition have shown significant clinical benefit in patients with BRAFV600-mutant metastatic melanoma. This study aimed to determine the best initial treatment or treatment sequence in this population.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Add to Collection

Review Medicine, General & Internal

Screening for Skin Cancer: US Preventive Services Task Force Recommendation Statement

Carol M. Mangione et al.

Summary: Skin cancer is the most commonly diagnosed cancer in the US, with different types varying in incidence and severity. Basal and squamous cell carcinomas are the most common types, while melanomas cause the most skin cancer deaths. Melanoma is 30 times more common in white people than black people, but darker-skinned individuals are often diagnosed at later stages.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2023)

Add to Collection

Review Oncology

Neoadjuvant Checkpoint Immunotherapy and Melanoma: The Time Is Now

Georgina V. Long et al.

Summary: The role of neoadjuvant therapy is shifting in oncology, from reducing surgical morbidity to a life-saving treatment with curative promise. Recent studies suggest that checkpoint inhibitors administered in the neoadjuvant setting may have greater clinical efficacy compared to the adjuvant setting.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Add to Collection

Article Oncology

Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial

Paolo Antonio Ascierto et al.

Summary: Preliminary research shows that nivolumab and relatlimab have better efficacy in treating advanced melanoma patients who have previously received anti-PD-(L)1 treatment. The RELATIVITY-047 trial demonstrated that nivolumab and relatlimab, compared to nivolumab alone, significantly improved progression-free survival in previously untreated advanced melanoma patients.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Add to Collection

Review Dermatology

Clinical management of melanocytic tumours of uncertain malignant potential (MelTUMPs), including melanocytomas: A systematic review and meta-analysis

Alexander H. R. Varey et al.

Summary: This review evaluated the management and prognostic utility of excision margins and sentinel node biopsy (SNB) for patients with melanocytic tumors of uncertain or low malignant potential. The findings indicate a lack of clear guidance on optimal excision margins and the limited prognostic value of SNB for this tumor type. Therefore, routine SNB should not be offered for these tumors.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2023)

Add to Collection

News Item Dermatology

Neoadjuvant pembrolizumab improves eventfree survival in melanoma

T. Schwarz

JOURNAL OF INVESTIGATIVE DERMATOLOGY (2023)

Add to Collection

Article Oncology

Brain metastasis and survival outcomes after first-line therapy in metastatic melanoma: a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREG

Cindy Franklin et al.

Summary: This study investigated the impact of first-line therapy on the incidence of brain metastasis and survival outcomes in patients with advanced melanoma. It found that BRAF mutant patients treated with PD-1 +/- CTLA-4 inhibitors had a lower occurrence and delayed development of brain metastasis compared to BRAF+MEK targeted therapy. Furthermore, first-line therapy with CTLA-4+PD-1 showed superior overall survival compared to PD-1 and BRAF+MEK.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2023)

Add to Collection

Article Medicine, General & Internal

Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma

Sapna P. Patel et al.

Summary: This study aimed to investigate whether giving pembrolizumab both before and after surgery would improve event-free survival in patients with resectable stage III or IV melanoma. Results showed that patients who received pembrolizumab both before and after surgery had significantly longer event-free survival. Overall rating: 9 out of 10.

NEW ENGLAND JOURNAL OF MEDICINE (2023)

Add to Collection

Article Dermatology

Do we need to rethink the diagnoses melanoma in situ and severely dysplastic naevus?

Caitlin R. Semsarian et al.

BRITISH JOURNAL OF DERMATOLOGY (2022)

Add to Collection

Article Oncology

Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance

Felicity Newell et al.

Summary: This study examines the relationship between various factors and the response to immunotherapy in patients with advanced cutaneous melanoma. The results identify several factors associated with response and develop a multivariable model for predicting response. However, the study also indicates the presence of intratumor and intertumor heterogeneity in response to immunotherapy and the lack of clear biological mechanisms explaining non-predicted responses.

CANCER CELL (2022)

Add to Collection

Article Oncology

Sentinel lymph node melanoma metastases: Assessment of tumor burden for clinical prediction of outcome in the first Multicenter Selective Lymphadenectomy Trial (MSLT-I)

Alistair J. Cochran et al.

Summary: The precise characterization of sentinel lymph node (SLN) metastases is crucial for guiding the management of patients with Stage III melanoma. This study compared various methods of tumor burden quantification and found that the percentage of nodal involvement is a more powerful prognostic factor than the maximum dimension of the largest metastasis.

EJSO (2022)

Add to Collection

Article Oncology

Clinical Models to Define Response and Survival With Anti-PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma

Ines Pires da Silva et al.

Summary: This study aimed to build multivariable predictive models for response and survival outcomes in metastatic melanoma patients treated with immunotherapy. By analyzing clinical characteristics and baseline blood parameters, the final models for predicting treatment response, progression-free survival, and overall survival were developed and nomogram calculators were created.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Oncology

Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600-Mutant Unresectable or Metastatic Melanoma

Reinhard Dummer et al.

Summary: The COMBI-i trial evaluated the combination of spartalizumab with dabrafenib and trametinib in patients with BRAF V600-mutant unresectable or metastatic melanoma. The study did not meet its primary end point of progression-free survival, indicating that broad first-line use of this combination is not supported by the results. Further research is needed to identify patient subpopulations who may benefit from checkpoint inhibitor plus targeted therapy combinations.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Oncology

Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma

Jedd D. Wolchok et al.

Summary: The 6.5-year results of the CheckMate 067 trial demonstrate durable clinical benefits with nivolumab plus ipilimumab or nivolumab monotherapy compared to ipilimumab alone in patients with advanced melanoma.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Medicine, General & Internal

Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma

Hussein A. Tawbi et al.

Summary: LAG-3 and PD-1 are two distinct inhibitory immune checkpoints that contribute to T-cell exhaustion. The combination of relatlimab and nivolumab has been shown to be safe and effective in previously treated melanoma patients, and this study aimed to evaluate its safety and activity in previously untreated melanoma patients. The results demonstrated that the combination therapy provided a greater benefit in terms of progression-free survival compared to nivolumab alone, without any new safety signals.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Oncology

Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma

Kenneth F. Grossmann et al.

Summary: In a randomized phase III trial, adjuvant pembrolizumab was found to significantly improve recurrence-free survival (RFS) but not overall survival (OS) compared to the prior standard-of-care immunotherapies for high-risk resected melanoma patients. The proportion of treatment-related adverse events was lower with pembrolizumab compared to IFN alpha-2b or ipilimumab.

CANCER DISCOVERY (2022)

Add to Collection

Article Oncology

Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses

Claire F. Friedman et al.

Summary: This study compared the efficacy of different treatment methods in patients with advanced melanoma through a randomized trial. The results showed that both treatments could induce objective responses, with comparable disease control rates. The findings from biomarker analyses provided hypothesis-generating signals for further research.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

Add to Collection

Article Oncology

Evaluation of the Indications for Sentinel Node Biopsy in Early-Stage Melanoma with the Advent of Adjuvant Systemic Therapy: An International, Multicenter Study

Marc D. Moncrieff et al.

Summary: Patients with early-stage melanoma have a low SN-positivity rate, with most patients being reclassified as AJCC stage IIIA after SNB. Adjuvant systemic therapy is not routinely recommended for most patients with AJCC stage IIIA melanoma. The indications for SNB in some patients with early-stage melanoma need to be reevaluated.

ANNALS OF SURGICAL ONCOLOGY (2022)

Add to Collection

Review Oncology

European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022

Claus Garbe et al.

Summary: A unique collaboration of multidisciplinary experts has provided recommendations on diagnosis and treatment of cutaneous melanoma. The recommendations cover excision of melanomas, sentinel lymph node dissection, and systemic treatments.

EUROPEAN JOURNAL OF CANCER (2022)

Add to Collection

Article Medicine, General & Internal

Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial

Jason J. Luke et al.

Summary: The study demonstrates that Pembrolizumab as adjuvant therapy significantly prolongs recurrence-free survival in patients with stage II melanoma, with manageable safety profile.

LANCET (2022)

Add to Collection

Letter Medicine, General & Internal

CTLA-4 Blockade Resistance after Relatlimab and Nivolumab

Alexander M. Menzies et al.

Summary: The study suggests that tumors that become resistant to PD-1 and LAG-3 therapy may also develop cross-resistance to ipilimumab.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Oncology

Differences in Thickness-Specific Incidence and Factors Associated With Cutaneous Melanoma in the US From 2010 to 2018

Michael L. Chen et al.

Summary: This study aims to evaluate recent patterns in the incidence of melanoma by tumor thickness and examine associations with sex, race and ethnicity, and socioeconomic status. The findings suggest that the incidence of the thickest melanoma tumors increased from 2010 to 2018, while the incidence patterns for thinner melanomas remained stable. Patients with low socioeconomic status and Hispanic patients were more likely to be diagnosed with thick melanoma.

JAMA ONCOLOGY (2022)

Add to Collection

Article Medicine, General & Internal

Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma

Maartje W. Rohaan et al.

Summary: This phase 3 trial demonstrates that patients with advanced melanoma who received TIL therapy had significantly longer progression-free survival compared to those who received ipilimumab.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Oncology

Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort study

F. Dimitriou et al.

Summary: Mucosal melanoma (MM) is a rare subtype of melanoma with poor prognosis. The efficacy of immune checkpoint inhibitors (ICIs) in treating MM appears to be consistent across different ethnicities and primary sites. Combination therapy with anti-PD-1 and ipilimumab shows a slightly higher response rate in naso-oral primaries.

ANNALS OF ONCOLOGY (2022)

Add to Collection

Article Oncology

COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With BRAF V600-Mutant Melanoma

Reinhard Dummer et al.

Summary: In patients with BRAF V600-mutant melanoma, the combination treatment of encorafenib plus binimetinib showed continued long-term benefits and a consistent safety profile over 5 years.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Oncology

Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination

Ana Arance et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Oncology

Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL) : a multicentre, open-label, single-arm, phase 2 study

Reinhard Dummer et al.

Summary: This study evaluated the use of atezolizumab in combination with cobimetinib or vemurafenib plus cobimetinib for patients with melanoma with CNS metastases. The results showed that the combination of atezolizumab and vemurafenib plus cobimetinib provided promising intracranial activity in patients with BRAF(V60)-mutated melanoma with CNS metastases.

LANCET ONCOLOGY (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial

Irene L. M. Reijers et al.

Summary: Neoadjuvant ipilimumab and nivolumab induce high pathologic response rates in clinical stage III nodal melanoma, with potential for treatment personalization based on pathologic response.

NATURE MEDICINE (2022)

Add to Collection

Article Pathology

Diagnostic utility of PRAME, p53 and 5-hmC immunostaining for distinguishing melanomas from naevi, neurofibromas, scars and other histological mimics

Robert Rawson et al.

Summary: This study investigated the utility of PRAME, p53, and 5-hmC immunostains for diagnosing melanocytic tumors. The study found that PRAME expression was significantly higher in melanomas compared to naevi, while 5-hmC expression was significantly lower. Combining PRAME and 5-hmC scores increased sensitivity for detecting melanoma. Strong PRAME and p53 staining were observed in high-grade desmoplastic melanomas, while low-grade desmoplastic melanomas, neurofibromas, and scars were negative. 5-hmC was not useful in distinguishing desmoplastic melanomas from neurofibromas or scars.

PATHOLOGY (2022)

Add to Collection

Article Multidisciplinary Sciences

Disparities in dermatology AI performance on a diverse, curated clinical image set

Roxana Daneshjou et al.

Summary: An estimated 3 billion people lack access to dermatological care globally. Artificial intelligence (AI) may aid in triaging skin diseases and identifying malignancies. However, most AI models have not been assessed on images of diverse skin tones or uncommon diseases.

SCIENCE ADVANCES (2022)

Add to Collection

Article Medicine, General & Internal

Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial

Lisa Zimmer et al.

Summary: The IMMUNED trial showed significant improvements in recurrence-free survival for adjuvant nivolumab plus ipilimumab as well as for adjuvant nivolumab alone in patients with stage IV melanoma with no evidence of disease after resection or radiotherapy. These positive results provide new options for the treatment of patients with stage IV melanoma with no evidence of disease.

LANCET (2022)

Add to Collection

Article Oncology

Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre double-blind, randomised, phase 3 trial

Georgina Long et al.

Summary: Adjuvant pembrolizumab is an efficacious treatment option for resected stage IIB and IIC melanoma, with a significant improvement in distant metastasis-free survival compared to placebo and continued reduction in the risk of recurrence. The adverse event profile of pembrolizumab is consistent with previous studies.

LANCET ONCOLOGY (2022)

Add to Collection

Article Multidisciplinary Sciences

Neoadjuvant relatlimab and nivolumab in resectable melanoma

Rodabe N. Amaria et al.

Summary: The combination of Relatlimab and nivolumab improves progression-free survival and has a high pathologic complete response rate in patients with advanced melanoma. This new immunotherapy regimen shows favorable safety compared to other combination immunotherapy regimens.

NATURE (2022)

Add to Collection

Article Oncology

Comparative Genomics Provides Etiologic and Biological Insight into Melanoma Subtypes

Felicity Newell et al.

Summary: This is the largest whole-genome analysis of melanoma to date, comprehensively comparing the genomics of the four major melanoma subtypes. This study highlights both similarities and differences between the subtypes, providing insights into the etiology and biology of melanoma.

CANCER DISCOVERY (2022)

Add to Collection

Article Surgery

Predicting recurrence in patients with sentinel node-negative melanoma: validation of theEORTCnomogram using population-based data

M. A. El Sharouni et al.

Summary: The study validated the prognostic model proposed by the EORTC Melanoma Group in predicting recurrence-free survival in patients with sentinel node-negative melanoma. The model could be beneficial in personalizing follow-up and identifying high-risk patients for adjuvant systemic therapy trials.

BRITISH JOURNAL OF SURGERY (2021)

Add to Collection

Article Pathology

Clinical, morphologic, and genomic findings inROS1fusion Spitz neoplasms

Pedram Gerami et al.

Summary: ROS1 fusion Spitz neoplasms exhibit typical microscopic features, with potential overlap with other genomic subtypes of Spitz neoplasms, and tend to be indolent or low-grade tumors in most cases.

MODERN PATHOLOGY (2021)

Add to Collection

Article Oncology

Cutaneous melanoma attributable to UVR exposure in Denmark and Germany

Ulrike Keim et al.

Summary: The increasing incidence rates of cutaneous melanoma in Denmark and Germany are largely attributed to exposure to solar ultraviolet radiation, emphasizing the importance of prevention strategies.

EUROPEAN JOURNAL OF CANCER (2021)

Add to Collection

Editorial Material Medicine, General & Internal

The Rapid Rise in Cutaneous Melanoma Diagnoses

H. Gilbert Welch et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Oncology

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Hyuna Sung et al.

Summary: The global cancer burden in 2020 saw an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths. Female breast cancer surpassed lung cancer as the most commonly diagnosed cancer, while lung cancer remained the leading cause of cancer death. These trends are expected to rise in 2040, with transitioning countries experiencing a larger increase compared to transitioned countries due to demographic changes and risk factors associated with globalization and a growing economy. Efforts to improve cancer prevention measures and provision of cancer care in transitioning countries will be crucial for global cancer control.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

Add to Collection

Article Oncology

Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study

Hussein A. Tawbi et al.

Summary: The study demonstrated the durable response, overall survival, and progression-free survival rates for asymptomatic patients treated with nivolumab plus ipilimumab. In contrast, the efficacy was lower in symptomatic patients. Treatment-related adverse events were mainly mild to moderate.

LANCET ONCOLOGY (2021)

Add to Collection

Article Oncology

Development and Validation of Nomograms to Predict Local, Regional, and Distant Recurrence in Patients With Thin (T1) Melanomas

Mary-Ann El Sharouni et al.

Summary: Although most patients with thin melanomas have a good prognosis, some may experience recurrence. The developed model in this study accurately identifies a subgroup at high risk.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma

E. A. Rozeman et al.

Summary: The combination of neoadjuvant ipilimumab plus nivolumab showed high pathologic response rates (pRRs) in patients with macroscopic stage III melanoma. High tumor mutational burden (TMB) and high interferon-gamma-related gene expression signature score (IFN-gamma score) were associated with pathologic response and a low risk of relapse. These findings support the potential predictive value of TMB and IFN-gamma score in the treatment of melanoma patients.

NATURE MEDICINE (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)

Alexander M. Menzies et al.

Summary: A pooled analysis of neoadjuvant immunotherapy trials in melanoma revealed that the degree of pathological response is correlated with patient survival, serving as a potential surrogate marker for long-term outcomes. Patients with pathological complete response (pCR) after immunotherapy showed significantly improved recurrence-free survival (RFS) and overall survival (OS) compared to those without pCR. Pathological response, particularly pCR, could be an early surrogate endpoint for clinical trials and a new benchmark for development and approval in melanoma.

NATURE MEDICINE (2021)

Add to Collection

Article Oncology

Active surveillance of patients who have sentinel node positive melanoma: An international, multi-institution evaluation of adoption and early outcomes after the Multicenter Selective Lymphadenectomy trial II (MSLT-2)

Kristy Kummerow Broman et al.

Summary: For patients with sentinel lymph node-positive cutaneous melanoma, real-world outcomes align with randomized trial findings, showing that most patients now adopt active surveillance with equivalent survival outcomes. Adjuvant therapy improves all-site recurrence-free survival, while nodal management or adjuvant treatment do not affect disease-specific survival or distant metastasis-free survival.

CANCER (2021)

Add to Collection

Article Oncology

Cancer statistics for the year 2020: An overview

Jacques Ferlay et al.

Summary: The study briefly reviews the methods and data sources used in compiling the IARC GLOBOCAN cancer statistics for 2020 and summarizes the main results. It estimated that there were nearly 19.3 million new cancer cases and almost 10 million cancer deaths worldwide in 2020, with the most commonly diagnosed cancers being female breast cancer and lung cancer, and the most common causes of cancer death being lung cancer and liver cancer.

INTERNATIONAL JOURNAL OF CANCER (2021)

Add to Collection

Review Oncology

Indoor Tanning and the Risk of Overall and Early-Onset Melanoma and Non-Melanoma Skin Cancer: Systematic Review and Meta-Analysis

Seokyung An et al.

Summary: This study reviewed 54 studies and found that indoor tanning is associated with early-onset melanoma and NMSC, with higher risk in younger individuals. The findings emphasize the importance of avoiding indoor tanning in younger adults to reduce the risk of skin cancer.

CANCERS (2021)

Add to Collection

Article Oncology

Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma

Daniel J. Olson et al.

Summary: This study is the first prospective study in melanoma of pembrolizumab plus low-dose ipilimumab after anti-PD-1/L1 immunotherapy failure, demonstrating significant antitumor activity and tolerability.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Article Oncology

Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study

Ines Pires da Silva et al.

Summary: The study indicates that for patients resistant to anti-PD-(L)1, ipilimumab plus anti-PD-1 appears to offer higher efficacy compared to ipilimumab monotherapy, with a higher objective response rate, prolonged progression-free survival, longer overall survival, and a similar rate of grade 3-5 toxicity.

LANCET ONCOLOGY (2021)

Add to Collection

Article Oncology

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial

Alexander M. M. Eggermont et al.

Summary: The study demonstrated that adjuvant pembrolizumab therapy can improve the 3.5-year distant metastasis-free survival in patients with resected high-risk stage III cutaneous melanoma, with a more significant effect in patients with PD-L1-positive tumors.

LANCET ONCOLOGY (2021)

Add to Collection

Article Oncology

Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204)

Hussein A. Tawbi et al.

Summary: The combination of nivolumab and ipilimumab shows durable clinical benefit for asymptomatic patients with melanoma brain metastases, but has limited activity in patients with neurological symptoms and/or requiring corticosteroids.

NEURO-ONCOLOGY (2021)

Add to Collection

Article Pathology

Impact of Next-generation Sequencing on Interobserver Agreement and Diagnosis of Spitzoid Neoplasms

Sarah Benton et al.

Summary: The study found that additional genomic information can help improve diagnostic agreement and accuracy among expert pathologists when assessing tumors with Spitzoid features, particularly in diagnosing conventional melanoma and classifying lesions into the Spitz category/WHO Pathway.

AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2021)

Add to Collection

Article Oncology

5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAF(V600) Mutation-Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study

Paolo A. Ascierto et al.

Summary: The long-term follow-up of the coBRIM study confirmed the extended clinical benefit and safety profile of cobimetinib plus vemurafenib compared to vemurafenib monotherapy in patients with BRAF(V600) mutation-positive advanced melanoma. The study showed improved progression-free survival and overall survival in the cobimetinib plus vemurafenib group, with the safety profile remaining consistent with previous reports.

CLINICAL CANCER RESEARCH (2021)

Add to Collection

Article Oncology

Re-defining the role of surgery in the management of patients with oligometastatic stage IV melanoma in the era of effective systemic therapies

Sydney Ch'ng et al.

Summary: Surgery has been traditionally important in treating oligometastatic stage IV melanoma patients, but with the development of effective systemic therapies, especially immunotherapy, the role of surgery has evolved. The decision between upfront surgery and immunotherapy needs to be made in a specialist melanoma multidisciplinary setting tailored to individual patient and tumor factors. High-level clinical trial evidence is necessary to address uncertainties in managing these patients, though the complexity of disease presentations may pose challenges in trial design.

EUROPEAN JOURNAL OF CANCER (2021)

Add to Collection

Article Pathology

Histological regression in melanoma: impact on sentinel lymph node status and survival

Karina Aivazian et al.

Summary: The regression in primary cutaneous melanoma is a favorable prognostic factor, especially when it occurs simultaneously with TILs. However, in Stage III melanoma patients, regression may be a marker of more aggressive disease.

MODERN PATHOLOGY (2021)

Add to Collection

Article Health Care Sciences & Services

Stress testing reveals gaps in clinic readiness of image-based diagnostic artificial intelligence models

Albert T. Young et al.

Summary: This study systematically assessed the performance of artificial intelligence models, specifically convolutional neural networks, on real-world non-curated images using computational stress tests. Results showed inconsistent predictions on images subjected to repeated capture or simple transformations, indicating the need for further validation of models meeting conventionally reported metrics.

NPJ DIGITAL MEDICINE (2021)

Add to Collection

Review Dermatology

Evidence-Based Clinical Practice Guidelines for the Management of Patients with Lentigo Maligna

Mitchell Robinson et al.

DERMATOLOGY (2020)

Add to Collection

Article Pathology

Melanoma pathology reporting and staging

Richard A. Scolyer et al.

MODERN PATHOLOGY (2020)

Add to Collection

Review Medical Laboratory Technology

The 2018 World Health Organization Classification of Cutaneous, Mucosal, and Uveal Melanoma Detailed Analysis of 9 Distinct Subtypes Defined by Their Evolutionary Pathway

David E. Elder et al.

ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2020)

Add to Collection

Article Oncology

Cumulative Incidence and Predictors of CNS Metastasis for Patients With American Joint Committee on Cancer 8th Edition Stage III Melanoma

Lauren E. Haydu et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Article Oncology

Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial

Reinhard Dummer et al.

LANCET ONCOLOGY (2020)

Add to Collection

Article Public, Environmental & Occupational Health

New Systematic Therapies and Trends in Cutaneous Melanoma Deaths Among US Whites, 1986-2016

Juliana Berk-Krauss et al.

AMERICAN JOURNAL OF PUBLIC HEALTH (2020)

Add to Collection

Review Dermatology

Prognostic Gene Expression Profiling in Cutaneous Melanoma Identifying the Knowledge Gaps and Assessing the Clinical Benefit

Douglas Grossman et al.

JAMA DERMATOLOGY (2020)

Add to Collection

Article Oncology

Improved Risk Prediction Calculator for Sentinel Node Positivity in Patients With Melanoma: The Melanoma Institute Australia Nomogram

Serigne N. Lo et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Article Medicine, Research & Experimental

The Melanoma Genomics Managing Your Risk Study randomised controlled trial: statistical analysis plan

Serigne N. Lo et al.

TRIALS (2020)

Add to Collection

Letter Medicine, General & Internal

Geographic Distribution of US Cohorts Used to Train Deep Learning Algorithms

Amit Kaushal et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

Add to Collection

Article Oncology

Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial

Alexander M. M. Eggermont et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Article Oncology

Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma

Caroline Robert et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Article Oncology

Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial

Paolo A. Ascierto et al.

LANCET ONCOLOGY (2020)

Add to Collection

Article Medicine, General & Internal

Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma

Reinhard Dummer et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Oncology

Identification of stage I/IIA melanoma patients at high risk for disease relapse using a clinicopathologic and gene expression model

Alexander M. M. Eggermont et al.

EUROPEAN JOURNAL OF CANCER (2020)

Add to Collection

Review Oncology

MITF and UV responses in skin: From pigmentation to addiction

Nhu T. Nguyen et al.

PIGMENT CELL & MELANOMA RESEARCH (2019)

Add to Collection

Article Dermatology

Identification of patients at risk of metastasis using a prognostic 31-gene expression profile in subpopulations of melanoma patients with favorable outcomes by standard criteria

Brian R. Gastman et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2019)

Add to Collection

Article Oncology

Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial

Celeste Lebbe et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

Add to Collection

Article Biochemistry & Molecular Biology

A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma

Alexander C. Huang et al.

NATURE MEDICINE (2019)

Add to Collection

Article Oncology

Incidence, features and management of radionecrosis in melanoma patients treated with cerebral radiotherapy and anti-PD-1 antibodies

Ines Pires da Silva et al.

PIGMENT CELL & MELANOMA RESEARCH (2019)

Add to Collection

Editorial Material Dermatology

Commentary: Position statement on augmented intelligence (AuI)

Carrie Kovarik et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2019)

Add to Collection

Review Oncology

Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium

Rodabe N. Amaria et al.

LANCET ONCOLOGY (2019)

Add to Collection

Article Oncology

Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial

Elisa A. Rozeman et al.

LANCET ONCOLOGY (2019)

Add to Collection

Article Oncology

Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial

Georgina V. Long et al.

LANCET ONCOLOGY (2019)

Add to Collection

Article Oncology

Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study

Caroline Robert et al.

LANCET ONCOLOGY (2019)

Add to Collection

Article Medicine, General & Internal

Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma

C. Robert et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Article Multidisciplinary Sciences

Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets

Felicity Newel et al.

NATURE COMMUNICATIONS (2019)

Add to Collection

Article Oncology

Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III- IV melanoma

Robert H. Andtbacka et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)

Add to Collection

Article Oncology

Final Analysis of DeCOG-SLT Trial: No Survival Benefit for Complete Lymph Node Dissection in Patients With Melanoma With Positive Sentinel Node

Ulrike Leiter et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

Add to Collection

Article Dermatology

Having a first-degree relative with melanoma increases lifetime risk of melanoma, squamous cell carcinoma, and basal cell carcinoma

Erin X. Wei et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2019)

Add to Collection

Article Medicine, General & Internal

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

J. Larkin et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Article Dermatology

Guidelines of care for the management of primary cutaneous melanoma

Susan M. Swetter et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2019)

Add to Collection

Article Pathology

Filigree-like Rete Ridges, Lobulated Nests, Rosette-like Structures, and Exaggerated Maturation Characterize Spitz Tumors With NTRK1 Fusion

Iwei Yeh et al.

AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2019)

Add to Collection

Article Oncology

Generational shift in melanoma incidence and mortality in Queensland, Australia, 1995-2014

Joanne F. Aitken et al.

INTERNATIONAL JOURNAL OF CANCER (2018)

Add to Collection

Article Oncology

Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma

M. T. Tetzlaff et al.

ANNALS OF ONCOLOGY (2018)

Add to Collection

Article Oncology

Global burden of cutaneous melanoma attributable to ultraviolet radiation in 2012

Melina Arnold et al.

INTERNATIONAL JOURNAL OF CANCER (2018)

Add to Collection

Review Medicine, General & Internal

Behavioral Counseling to Prevent Skin Cancer US Preventive Services Task Force Recommendation Statement

David C. Grossman et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)

Add to Collection

Article Oncology

Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial

Reinhard Dummer et al.

LANCET ONCOLOGY (2018)

Add to Collection

Article Oncology

Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study

Georgina V. Long et al.

LANCET ONCOLOGY (2018)

Add to Collection

Article Oncology

Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial

Rodabe N. Amaria et al.

LANCET ONCOLOGY (2018)

Add to Collection

Article Medicine, General & Internal

Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma

Alexander M. M. Eggermont et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Letter Dermatology

Trends in Melanoma Incidence Among Non-Hispanic Whites in the United States. 2005 to 2014

Dawn M. Holman et al.

JAMA DERMATOLOGY (2018)

Add to Collection

Letter Oncology

Immunotherapy and Symptomatic Radiation Necrosis in Patients With Brain Metastases Treated With Stereotactic Radiation

Allison M. Martin et al.

JAMA ONCOLOGY (2018)

Add to Collection

Article Pathology

PRAME Expression in Melanocytic Tumors

Cecilia Lezcano et al.

AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2018)

Add to Collection

Article Multidisciplinary Sciences

High response rate to PD-1 blockade in desmoplastic melanomas

Zeynep Eroglu et al.

NATURE (2018)

Add to Collection

Article Medicine, General & Internal

Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain

Hussein A. Tawbi et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Editorial Material Dermatology

Machine Learning and Health Care Disparities in Dermatology

Adewole S. Adamson et al.

JAMA DERMATOLOGY (2018)

Add to Collection

Article Biochemistry & Molecular Biology

Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma

Rodabe N. Amaria et al.

NATURE MEDICINE (2018)

Add to Collection

Article Biochemistry & Molecular Biology

Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma

Christian U. Blank et al.

NATURE MEDICINE (2018)

Add to Collection

Article Oncology

Circulating tumor DNA predicts survival in patients with resected high-risk stage II/III melanoma

R. J. Lee et al.

ANNALS OF ONCOLOGY (2018)

Add to Collection

Article Oncology

Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma

M. H. Pollack et al.

ANNALS OF ONCOLOGY (2018)

Add to Collection

Review Oncology

Proportion and Number of Cancer Cases and Deaths Attributable to Potentially Modifiable Risk Factors in the United States

Farhad Islami et al.

CA-A CANCER JOURNAL FOR CLINICIANS (2018)

Add to Collection

Article Oncology

Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab

A. M. Menzies et al.

ANNALS OF ONCOLOGY (2017)

Add to Collection

Review Oncology

Adjuvant interferon-α for the treatment of high-risk melanoma: An individual patient data meta-analysis

Natalie J. Ives et al.

EUROPEAN JOURNAL OF CANCER (2017)

Add to Collection

Article Oncology

Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis

Sandra P. D'Angelo et al.

JOURNAL OF CLINICAL ONCOLOGY (2017)

Add to Collection

Article Oncology

Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial

Michael A. Davies et al.

LANCET ONCOLOGY (2017)

Add to Collection

Article Oncology

Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial

Paolo A. Ascierto et al.

LANCET ONCOLOGY (2017)

Add to Collection

Article Oncology

Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial

Georgina V. Long et al.

LANCET ONCOLOGY (2017)

Add to Collection

Article Multidisciplinary Sciences

Dermatologist-level classification of skin cancer with deep neural networks

Andre Esteva et al.

NATURE (2017)

Add to Collection

Article Multidisciplinary Sciences

Whole-genome landscapes of major melanoma subtypes

Nicholas K. Hayward et al.

NATURE (2017)

Add to Collection

Article Medicine, General & Internal

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

J. Weber et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection

Article Medicine, General & Internal

Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma

M. B. Faries et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection

Article Medicine, General & Internal

Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma

G. V. Long et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection

Article Oncology

A Large Skin Cancer Screening Quality Initiative Description and First-Year Outcomes

Laura K. Ferris et al.

JAMA ONCOLOGY (2017)

Add to Collection

Article Oncology

Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual

Jeffrey E. Gershenwald et al.

CA-A CANCER JOURNAL FOR CLINICIANS (2017)

Add to Collection

Review Oncology

Immune Checkpoint Inhibitors in Challenging Populations

Douglas B. Johnson et al.

CANCER (2017)

Add to Collection

Article Dermatology

The Growing Burden of Invasive Melanoma: Projections of Incidence Rates and Numbers of New Cases in Six Susceptible Populations through 2031

David C. Whiteman et al.

JOURNAL OF INVESTIGATIVE DERMATOLOGY (2016)

Add to Collection

Article Medicine, General & Internal

Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy

A. M. M. Eggermont et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

Add to Collection

Article Ophthalmology

Driver Mutations in Uveal Melanoma Associations With Gene Expression Profile and Patient Outcomes

Christina L. Decatur et al.

JAMA OPHTHALMOLOGY (2016)

Add to Collection

Article Oncology

Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma

E. Liniker et al.

ONCOIMMUNOLOGY (2016)

Add to Collection

Article Oncology

A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naive patients with metastatic melanoma

E. M. Hersh et al.

ANNALS OF ONCOLOGY (2015)

Add to Collection

Article Oncology

Five-Year Survival Rates for Treatment-Naive Patients With Advanced Melanoma Who Received Ipilimumab Plus Dacarbazine in a Phase III Trial

Michele Maio et al.

JOURNAL OF CLINICAL ONCOLOGY (2015)

Add to Collection

Article Oncology

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

Dirk Schadendorf et al.

JOURNAL OF CLINICAL ONCOLOGY (2015)

Add to Collection

Article Oncology

Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node field relapse after lymphadenectomy (ANZMTG 01.02/TROG 02.01): 6-year follow-up of a phase 3, randomised controlled trial

Michael A. Henderson et al.

LANCET ONCOLOGY (2015)

Add to Collection

Article Oncology

Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial

Alexander M. M. Eggermont et al.

LANCET ONCOLOGY (2015)

Add to Collection

Article Genetics & Heredity

Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathway

A. Hunter Shain et al.

NATURE GENETICS (2015)

Add to Collection

Article Medicine, General & Internal

Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib

Caroline Robert et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

Add to Collection

Article Medicine, General & Internal

Nivolumab in Previously Untreated Melanoma without BRAF Mutation

Caroline Robert et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

Add to Collection

Article Medicine, General & Internal

The Genetic Evolution of Melanoma from Precursor Lesions

A. Hunter Shain et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

Add to Collection

Article Medicine, General & Internal

Pembrolizumab versus Ipilimumab in Advanced Melanoma

Caroline Robert et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

Add to Collection

Article Medicine, General & Internal

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

J. Larkin et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

Add to Collection

Article Medicine, General & Internal

Melanoma mortality following skin cancer screening in Germany

Mathieu Boniol et al.

BMJ OPEN (2015)

Add to Collection

Article Oncology

Melanoma incidence trends and survival in adolescents and young adults in Queensland, Australia

Michelle R. Iannacone et al.

INTERNATIONAL JOURNAL OF CANCER (2015)

Add to Collection

Review Dermatology

Risk of subsequent cutaneous malignancy in patients with prior melanoma: a systematic review and meta-analysis

R. J. T. van der Leest et al.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2015)

Add to Collection

Article Public, Environmental & Occupational Health

More Skin, More Sun, More Tan, More Melanoma

Caroline Chang et al.

AMERICAN JOURNAL OF PUBLIC HEALTH (2014)

Add to Collection

Article Pathology

Clinical and Pathologic Findings of Spitz Nevi and Atypical Spitz Tumors With ALK Fusions

Klaus J. Busam et al.

AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2014)

Add to Collection

Article Oncology

Age as a Predictor of Sentinel Node Metastasis among Patients with Localized Melanoma: An Inverse Correlation of Melanoma Mortality and Incidence of Sentinel Node Metastasis Among Young and Old Patients

Charles M. Balch et al.

ANNALS OF SURGICAL ONCOLOGY (2014)

Add to Collection

Review Pathology

The Molecular Pathology of Melanoma: An Integrated Taxonomy of Melanocytic Neoplasia

Boris C. Bastian

ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 9 (2014)

Add to Collection

Article Medicine, General & Internal

Final Trial Report of Sentinel-Node Biopsy versus Nodal Observation in Melanoma

D. L. Morton et al.

NEW ENGLAND JOURNAL OF MEDICINE (2014)

Add to Collection

Article Medicine, General & Internal

Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma

G. V. Long et al.

NEW ENGLAND JOURNAL OF MEDICINE (2014)

Add to Collection

Article Medicine, General & Internal

Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma

James Larkin et al.

NEW ENGLAND JOURNAL OF MEDICINE (2014)

Add to Collection

Article Multidisciplinary Sciences

Kinase fusions are frequent in Spitz tumours and spitzoid melanomas

Thomas Wiesner et al.

NATURE COMMUNICATIONS (2014)

Add to Collection

Article Dermatology

Detection of Primary Melanoma in Individuals at Extreme High Risk A Prospective 5-Year Follow-up Study

Fergal J. Moloney et al.

JAMA DERMATOLOGY (2014)

Add to Collection

Article Oncology

Phase III Trial of Carboplatin and Paclitaxel With or Without Sorafenib in Metastatic Melanoma

Keith T. Flaherty et al.

JOURNAL OF CLINICAL ONCOLOGY (2013)

Add to Collection

Article Oncology

Preoperative Ultrasound is Not Useful for Identifying Nodal Metastasis in Melanoma Patients Undergoing Sentinel Node Biopsy: Preoperative Ultrasound in Clinically Node-Negative Melanoma

Christy Y. Chai et al.

ANNALS OF SURGICAL ONCOLOGY (2012)

Add to Collection

Article Oncology

Skin cancer screening participation and impact on melanoma incidence in Germany - an observational study on incidence trends in regions with and without population-based screening

A. Waldmann et al.

BRITISH JOURNAL OF CANCER (2012)

Add to Collection

Article Oncology

Risk Factors for Malignant Melanoma in White and Non-White/Non-African American Populations: The Multiethnic Cohort

Sungshim Lani Park et al.

CANCER PREVENTION RESEARCH (2012)

Add to Collection

Article Oncology

Tumor-Infiltrating Lymphocyte Grade Is an Independent Predictor of Sentinel Lymph Node Status and Survival in Patients With Cutaneous Melanoma

Farhad Azimi et al.

JOURNAL OF CLINICAL ONCOLOGY (2012)

Add to Collection

Article Dermatology

Increased diagnosis of thin superficial spreading melanomas: A 20-year study

Jason E. Frangos et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2012)

Add to Collection

Article Dermatology

Systematic skin cancer screening in Northern Germany

Eckhard W. Breitbart et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2012)

Add to Collection

Article Oncology

Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial

Bryan H. Burmeister et al.

LANCET ONCOLOGY (2012)

Add to Collection

Review Medicine, General & Internal

Melanoma in Immunosuppressed Patients

Agnieszka W. Kubica et al.

MAYO CLINIC PROCEEDINGS (2012)

Add to Collection

Article Oncology

Sunbed use during adolescence and early adulthood is associated with increased risk of early-onset melanoma

Anne E. Cust et al.

INTERNATIONAL JOURNAL OF CANCER (2011)

Add to Collection

Article Oncology

Reduced Melanoma After Regular Sunscreen Use: Randomized Trial Follow-Up

Adele C. Green et al.

JOURNAL OF CLINICAL ONCOLOGY (2011)

Add to Collection

Article Genetics & Heredity

Cancer and neurologic degeneration in xeroderma pigmentosum: long term follow-up characterises the role of DNA repair

Porcia T. Bradford et al.

JOURNAL OF MEDICAL GENETICS (2011)

Add to Collection

Article Medicine, General & Internal

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

Caroline Robert et al.

NEW ENGLAND JOURNAL OF MEDICINE (2011)

Add to Collection

Article Oncology

BRAF mutations in cutaneous melanoma are independently associated with age, anatomic site of the primary tumor, and the degree of solar elastosis at the primary tumor site

Juergen Bauer et al.

PIGMENT CELL & MELANOMA RESEARCH (2011)

Add to Collection

Article Pathology

Melanocytic Tumors of Uncertain Malignant Potential Results of a Tutorial Held at the XXIX Symposium of the International Society of Dermatopathology in Graz, October 2008

Lorenzo Cerroni et al.

AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2010)

Add to Collection

Article Oncology

Prognostic Factors in Cutaneous Desmoplastic Melanoma

Rajmohan Murali et al.

CANCER (2010)

Add to Collection

Article Oncology

Nonmelanoma Skin Cancer and the Risk of Second Primary Cancers: a Systematic Review

Lee Wheless et al.

CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2010)

Add to Collection

Article Oncology

Clinical whole-body skin examination reduces the incidence of thick melanomas

Joanne F. Aitken et al.

INTERNATIONAL JOURNAL OF CANCER (2010)

Add to Collection

Article Oncology

Non-Sentinel Node Risk Score (N-SNORE): A Scoring System for Accurately Stratifying Risk of Non-Sentinel Node Positivity in Patients With Cutaneous Melanoma With Positive Sentinel Lymph Nodes

Rajmohan Murali et al.

JOURNAL OF CLINICAL ONCOLOGY (2010)

Add to Collection

Article Medicine, General & Internal

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

F. Stephen Hodi et al.

NEW ENGLAND JOURNAL OF MEDICINE (2010)

Add to Collection

Article Oncology

Genetic and morphologic features for melanoma classification

Sigrid M. C. Broekaert et al.

PIGMENT CELL & MELANOMA RESEARCH (2010)

Add to Collection

Article Multidisciplinary Sciences

Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi

Catherine D. Van Raamsdonk et al.

NATURE (2009)

Add to Collection

Article Pathology

Diagnosis of cutaneous melanocytic tumours by four-colour fluorescence in situ hybridisation

Adrienne L. Morey et al.

PATHOLOGY (2009)

Add to Collection

Article Oncology

Microscopic tumor burden in sentinel lymph nodes predicts synchronous nonsentinel lymph node involvement in patients with melanoma

Jeffrey E. Gershenwald et al.

JOURNAL OF CLINICAL ONCOLOGY (2008)

Add to Collection

Article Medicine, General & Internal

Improving melanoma classification by integrating genetic and morphologic features

Amaya Viros et al.

PLOS MEDICINE (2008)

Add to Collection

Article Oncology

Accuracy of lymphatic mapping and sentinel lymph node biopsy after previous wide local excision in patients with primary melanoma

Christopher J. Gannon et al.

CANCER (2006)

Add to Collection

Article Dermatology

Presentation and detection of invasive melanoma in a high-risk population

M McPherson et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2006)

Add to Collection

Article Medicine, General & Internal

Distinct sets of genetic alterations in melanoma

JA Curtin et al.

NEW ENGLAND JOURNAL OF MEDICINE (2005)

Add to Collection

Article Oncology

Risk factors and individual probabilities of melanoma for whites

E Cho et al.

JOURNAL OF CLINICAL ONCOLOGY (2005)

Add to Collection

Review Oncology

Meta-analysis of risk factors for cutaneous melanoma: I. Common and atypical naevi

S Gandini et al.

EUROPEAN JOURNAL OF CANCER (2005)

Add to Collection

Review Oncology

Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure

S Gandini et al.

EUROPEAN JOURNAL OF CANCER (2005)

Add to Collection

Article Oncology

Determinants of BRAF mutations in primary melanomas

JL Maldonado et al.

JOURNAL OF THE NATIONAL CANCER INSTITUTE (2003)

Add to Collection

Article Oncology

Melanocytic nevi, solar keratoses, and divergent pathways to cutaneous melanoma

DC Whiteman et al.

JOURNAL OF THE NATIONAL CANCER INSTITUTE (2003)

Add to Collection

© Peeref 2019-2024. All rights reserved.